Khorana Risk Score for VTE in Cancer Patients

The Khorana Risk Score identifies ambulatory cancer patients starting chemotherapy who are at increased risk for venous thromboembolism.

Cancer type
Other0Lung+1Lymphoma+1Gynecologic+1Bladder+1Testicular+1Stomach+2Pancreas+2
Pre-chemotherapy platelet count ≥ 350 x 10^9/L
No0Yes+1
Hemoglobin level < 10 g/dL or using RBC growth factors
No0Yes+1
Pre-chemotherapy leukocyte count > 11x10^9/L
No0Yes+1
BMI ≥ 35 kg/m^2
No0Yes+1

Indications for Use

Used in ambulatory cancer patients starting systemic therapy to estimate 6‑month VTE risk and identify those with score ≥2 who may benefit from prophylaxis. Validated across multiple cohorts and used in trials such as AVERT (apixaban reduced VTE 4.2% vs 10.2% 1 [Level I evidence]). Guides selective prophylaxis per ASCO/ESMO recommendations and supports patient counseling on individualized VTE risk.

Insights & Cautions

Identifies higher VTE risk in chemotherapy outpatients but has modest discrimination and poor performance in several cancers (lung, pancreatic, hepatobiliary) 1. High‑risk groups (≥3) show clearer benefit from prophylaxis, supported by LMWH/DOAC trials (e.g., apixaban HR 0.41) 2. Avoid overreliance—many VTEs occur outside high‑risk strata 3. Use with caution in patients with high bleeding risk.